

Serial No.: 10/693,161
Jeppesen et al.
Filed: October 24, 2003
Transmitted via facsimile to: 571-273-8300

REMARKS

This amendment is submitted to more clearly define that which the applicant claims as the invention of the present application. Entry of this amendment is respectfully requested.

In this amendment, claims numbered 1, 2, 11, 33-36, 40, 42, and 45-47 are amended; claims numbered 37, 38, 41 and 44 are cancelled; and new claims numbered 48-53 are added. Accordingly, claims numbered 1-36, 39-40, 42-43 and 45-53 are pending and at issue.

The Examiner is hereby invited to contact the undersigned by telephone if there are any questions concerning this amendment or application. It is believed that the claims are in condition for allowance, and a determination to that effect is earnestly solicited.

Respectfully submitted,



Date: August 24, 2005

Rosemarie R. Wilk-Orescan, Reg. No. 45,220
Novo Nordisk Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5969